Actively Recruiting
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Led by Yang Li · Updated on 2024-01-03
50
Participants Needed
1
Research Sites
417 weeks
Total Duration
On this page
Sponsors
Y
Yang Li
Lead Sponsor
R
Ruijin Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.
CONDITIONS
Official Title
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathological diagnosis of malignant tumor
- Patient is 18 years old or younger
- Patient has germline or somatic p53 mutations shown to be partially or completely restored by arsenic trioxide in lab tests
- Measurable cancer lesions are present
- Guardian has agreed and signed informed consent
You will not qualify if you...
- Patients with one or more critical organ failures such as heart, brain, or kidney failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China, 510120
Actively Recruiting
Research Team
Y
Yang Li, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here